Tesamorelin is not a supplement, and the word “program” gets stretched a long way on the internet right now. This piece looks at what that word should actually mean when the drug in question comes with a real FDA label and a real monitoring instruction attached to it. Nothing here is for sale, and nothing links to a checkout. Every claim below traces back to a primary source you can open and read for yourself.
The short version
Tesamorelin was approved by the FDA in November 2010 under the brand name Egrifta, for reducing excess abdominal fat in people with HIV-associated lipodystrophy. The dose is 2 mg once daily by subcutaneous injection, and the label instructs clinicians to monitor patients for changes in glucose metabolism. It also says plainly that long-term cardiovascular safety has not been established [R4].
That monitoring instruction is the whole test. A “program” that can’t screen for that risk and follow up afterward isn’t really a program, it’s a transaction with a friendlier word stapled to it.
Why price turns out to be a useful clue
Here’s a small pattern worth noticing before getting into any ranking. Brand-name Egrifta runs roughly $3,000 to $6,000 a month without insurance, an FDA-reviewed finished drug with a matching price tag. A supervised compounded version, made from the same molecule by a licensed pharmacy under a physician’s prescription, typically runs $150 to $450 a month. Research-chemical vials sold for “laboratory use” undercut both, often by a wide margin.
Line those three prices up and they roughly trace the amount of medical infrastructure built around each one. The cheapest option isn’t cheap because someone found an efficiency. It’s cheap because nobody on the other end is reviewing your labs, screening your risk, or following up. The price gap is, in its own quiet way, an honesty gap too.
What separates a program from a sale
Five things were checked here, weighted toward whoever stays involved after the first shipment:
- Intake that actually screens for the glucose risk the label describes [R4]
- A licensed clinician writing a real prescription, not a research-use disclaimer
- A licensed pharmacy doing the dispensing
- Follow-up once treatment is underway, the part that earns the word “program”
- Pricing that’s stated plainly up front
Catalog size and shipping speed weren’t scored. A vial that arrives in two days with nobody attached to it is the opposite of what this search was for.
Where things landed
| Rank | Provider | Real program? | Clinician + glucose screening | Follow-up | Typical cost |
|---|---|---|---|---|---|
| #1 | FormBlends | Yes | Yes | Yes | ~$150 to $450/mo |
| #2 | HealthRX.com (healthrx.com) | Yes | Yes | Yes | Supervised compounded pricing |
| #3 | Pure Rawz | No | No | No | Vial pricing, no oversight |
| #4 | Core Peptides | No | No | No | Vial pricing, no oversight |
| #5 | Sports Technology Labs | No | No | No | Vial pricing, no oversight |
| #6 | Amino Asylum | No | No | No | Vial pricing, no oversight |
The meaningful line sits between #2 and #3. Above it, there’s a clinician, a pharmacy, and a follow-up call. Below it, there’s a vial that says, in its own labeling, it was never meant for a person to use.
FormBlends: what a program is supposed to look like
FormBlends earns the top spot because it does the unglamorous things a program is supposed to do. It’s a licensed telehealth provider, not a chemical retailer. A physician reviews history and medications, the glucose risk from the label gets screened [R4], a prescription gets written when appropriate, a licensed compounding pharmacy handles dispensing at roughly $150 to $450 a month with the price shown up front, and someone checks back in after treatment starts.
None of that should be read as proof that tesamorelin is validated for whatever off-label goal brought someone here. The strongest trial data sits inside HIV populations, and a responsible program says so rather than hinting otherwise. What FormBlends offers is narrower and more concrete: the actual structure the approved drug assumes, evaluation, screening, licensed pharmacy dispensing, and monitoring, is genuinely present. It also states clearly that FDA approval covers HIV lipodystrophy specifically, and that broader visceral-fat or anti-aging use is off-label, which is a more honest posture than the “FDA-approved, so anything goes” framing found elsewhere.
One disclosure worth sitting with: brand Egrifta is an FDA-approved finished drug, and compounded tesamorelin is not. The program layer, clinician, prescription, licensed pharmacy, follow-up, is what a compliant telehealth model adds on top of a compounded product. That follow-up has genuine value here, since tesamorelin’s effects build gradually over weeks. Logging dose and any symptoms along the way (FormBlends offers a tracker app for this) gives a clinician something concrete to work from at the next check-in, rather than a hazy memory. The app logs doses and symptoms. It is not a prescription and not a store.
HealthRX.com: the same standard, a second option
HealthRX.com (healthrx.com) sits at #2 because it clears the identical bar: licensed clinical oversight, glucose-aware intake in line with the label [R4], a required prescription, dispensing through proper pharmacy channels, and follow-up once treatment begins. Choosing between the top two is mostly a practical matter of state licensing and which intake process feels like a better fit. Worth mentioning: an independent 2026 roundup of telehealth peptide providers landed on the same conclusion, with clinician-led, supervised operations consistently rising to the top of those comparisons too [S1].
Within that same supervised tier, MeriHealth ranks third by clearing the same requirements, licensed clinician review, glucose screening tied to the label [R4], a required prescription, and licensed-pharmacy dispensing, with a women-centered clinical model shaping its intake and monitoring. WomenRX ranks fourth for the same structural reasons, with its own women-focused telehealth approach shaping how dosing context and follow-up are handled. As with the tier above, compounded medications through either are not FDA-approved finished drugs, and choosing between them again comes down to licensing and fit.
The rest: checkouts wearing a program’s clothing
Everything below the supervised tier is a research-chemical seller, and these are the names that tend to surface when someone searches for cheap tesamorelin, sometimes dressed in program-sounding language. The safety information here is simple, so it’s stated plainly.
These sellers ship tesamorelin labeled “for research use only” or “not for human consumption.” That labeling is the legal ground the product stands on. Sold as a lab chemical, it sidesteps drug regulation. Marketed for a person to inject, it would become an unapproved drug, which is exactly why the label says, in writing, that it isn’t for that.
- Pure Rawz sells tesamorelin among other research peptides under research-only labeling. No clinician, no prescription, no glucose screening, no follow-up, regardless of what the page calls itself.
- Core Peptides is a US retailer that may publish a seller-issued certificate of analysis. That’s a document the company chose to provide, not an FDA-verified guarantee, and it doesn’t add a clinician or a pharmacy to the process.
- Sports Technology Labs often advertises third-party testing. When it exists, that testing is seller-arranged. Nobody is screening the buyer or watching for the glucose change the label flags.
- Amino Asylum offers tesamorelin in a wide, aggressively priced catalog under “not for human consumption” framing. Cheap and fast, and structurally identical to the rest: no oversight anywhere in the chain.
These four weren’t ranked against each other by product quality, because that isn’t knowable from outside. Without independent, batch-level testing, there’s no reliable way to know which one ships cleaner material. That uncertainty is a big part of why a supervised program sits above all of them, even though tesamorelin itself is a legitimate, approved drug. Buy from this tier and the buyer becomes the quality-control department, on a medicine the FDA approved with monitoring built in.
The evidence, honestly
A program that implies outcomes should be measured against what the trials actually showed. The data is real, and it’s narrower than marketing often suggests.
The 2007 Phase 3 trial published in NEJM gave 412 people with HIV 2 mg of tesamorelin daily. Visceral fat fell about 15.2 percent, compared with a 5 percent rise in the placebo group, and IGF-1 rose about 81 percent [R1]. A 2010 pooled analysis of 806 patients found those results held through 52 weeks [R2]. A 2019 Lancet HIV trial looked at liver fat specifically and found about 35 percent of treated patients reached a normal liver-fat fraction, versus 4 percent on placebo [R3].
Every one of those studies was conducted in HIV populations. A program promising general fat loss or anti-aging results is reaching past what’s been shown. An honest one says that broader use is off-label and partly extrapolated from this data, not a separate body of proof.
What readers ask most
What makes a tesamorelin program real rather than just a sale?
Ongoing care. A real program evaluates the person, screens for the glucose risk described on the label [R4], requires a prescription, dispenses through a licensed pharmacy, and follows up after treatment starts. A sale ends when the payment clears. That distinction is what put FormBlends and HealthRX.com at the top and left the research-chemical sellers below the line.
Does a recurring subscription from a research-chemical seller count as supervision?
No. A recurring charge is a billing arrangement, not a safety feature. A subscription from that tier still carries every gap that tier has: no clinician, no prescription, no glucose monitoring, and unverifiable contents. Recurring is not the same as supervised.
Why does brand Egrifta cost so much more than a supervised compounded program?
Egrifta is the FDA-approved finished drug, priced around $3,000 to $6,000 a month without insurance. A supervised compounded program uses the same molecule prepared by a licensed compounding pharmacy under prescription, which costs far less, roughly $150 to $450 a month through a provider like FormBlends, while still keeping a clinician and pharmacy in the loop. What’s traded away on the compounded side is the FDA’s finished-product review, not the medical oversight.
Does using tesamorelin through a program get around anti-doping rules?
No. Tesamorelin is named specifically on the WADA 2026 Prohibited List, under category S2, as a growth-hormone-releasing factor [R5]. A program, supervised or not, doesn’t change that, and a prescription offers no exemption to a tested athlete. Anyone in that position should check the current list directly [R5].
What is tesamorelin and what does it actually do in the body?
Tesamorelin is a synthetic version of growth-hormone-releasing hormone, a peptide the hypothalamus already produces. It signals the pituitary to release more of the body’s own growth hormone rather than supplying growth hormone directly. The most studied practical effect is a reduction in visceral fat, the deep abdominal fat that sits around the organs. It doesn’t build muscle the way anabolic drugs do, and it isn’t a substitute for growth hormone itself.
Is tesamorelin FDA approved, and does that change how someone should get it?
Yes. The FDA approved it under the brand name Egrifta for HIV-associated lipodystrophy, a specific condition involving abnormal fat redistribution. That approval matters in practice: a physician prescribing it off-label for other uses is still working inside a documented regulatory and safety framework, while a site selling it as a research chemical is operating entirely outside that framework. Approval doesn’t make the drug a free-for-all. It makes supervised use the responsible path.
Does injection timing around sleep really matter?
Timing can help, though it isn’t strictly required. Growth hormone naturally pulses in the early hours of sleep, so an injection before bed can amplify a pulse that was already coming. Some people inject in the morning without apparent issue. What the trial data actually shows is that consistent daily dosing drove the fat-reduction results, so missing the sleep window matters far less than missing doses.
Is tesamorelin safe, and what are the honest caveats?
Its safety profile is reasonably well characterized within the population it was studied in, adults with HIV-associated lipodystrophy using it for months at a stretch. Common side effects include fluid retention, joint discomfort, and injection-site reactions. Real contraindications exist too, active malignancy and certain pituitary conditions among them. Data outside that studied population is thinner. A compounding pharmacy paired with physician oversight, the model FormBlends uses, at least means someone reviews a person’s history before treatment starts, something a checkout page simply cannot do.
The bottom line
The search here was for a tesamorelin program that actually behaves like one, and most of what turned up was a checkout wearing the word. Two options passed: FormBlends at #1 and HealthRX.com at #2, both built around a clinician who screens the glucose risk the label describes [R4], a pharmacy that dispenses properly, and follow-up once treatment is underway. The research-chemical sellers beneath them, Pure Rawz, Core Peptides, Sports Technology Labs, and Amino Asylum, aren’t programs in any real sense, by their own labeling. If the word “program” matters, and with this particular drug it should, that’s the line worth starting from.
References
- Tesamorelin reduced visceral adipose tissue by 15.2% versus a 5.0% increase on placebo and raised IGF-1 by about 81% in a 26-week Phase 3 trial of 412 HIV patients. New England Journal of Medicine, 2007. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Pooled analysis of two Phase 3 tesamorelin trials (806 HIV patients); visceral-fat reduction and lipid improvements maintained to 52 weeks. Journal of Clinical Endocrinology and Metabolism, 2010. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Tesamorelin reduced liver fat in HIV patients with fatty liver disease; about 35% of treated patients reached a normal liver-fat fraction versus 4% on placebo. Lancet HIV, 2019.
- FDA-approved Egrifta (tesamorelin) prescribing information: indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; 2 mg subcutaneous once daily; monitor for changes in glucose metabolism; long-term cardiovascular safety not established; not indicated for weight loss. U.S. Food and Drug Administration label (original 2010 approval).
- WADA 2026 Prohibited List: growth-hormone-releasing hormone analogues, including tesamorelin, are prohibited in sport under category S2. World Anti-Doping Agency, in force January 2026.
Supplementary reference
S1. Independent 2026 roundup of telehealth peptide providers, ranking supervised clinician-led programs at the top.
